| SAMIL-PHARM-CO-LTD |
SAMIL-PHARM-CO-LTD |
85%
|
roduct sales to date, although we have historically generated revenue from our licensing agreement with Samil Pharm. Co., Ltd., or Samil. We have incurred operating losses in each year since the ince… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: til February 2011. Previously, she … |
| GILD |
Gilead Sciences, Inc. |
72%
|
til February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most rece… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from GLMD graph: incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximate… |
| JNJ |
Johnson & Johnson |
72%
|
incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $210.8 million and positive working capital (current assets less current liabi… |
| MTVA |
MetaVia Inc. |
72%
|
Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our sec… |
| VKTX |
Viking Therapeutics, Inc. |
72%
|
Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica… |
| CORPORATE-STRUCTURE-GALMED-PHARMACEUTICALS-LTD |
CORPORATE-STRUCTURE-GALMED-PHARMACEUTICALS-LTD |
62%
|
ions to which you are entitled as an investor. 53 If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordi… |
| CVI-INVESTMENTS-INC |
CVI-INVESTMENTS-INC |
62%
|
til February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most rece… |
| GALMED-INTERNATIONAL-LIMITED |
GALMED-INTERNATIONAL-LIMITED |
62%
|
ions to which you are entitled as an investor. 53 If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordi… |
| GALMED-INTERNATIONAL-LTD |
GALMED-INTERNATIONAL-LTD |
62%
|
. The Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development Ltd. (“GRD”) and Galtopa Therapeutics Ltd., both of… |
| GALMED-MEDICAL-RESEARCH-LTD |
GALMED-MEDICAL-RESEARCH-LTD |
62%
|
ions to which you are entitled as an investor. 53 If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordi… |
| GALMED-THERAPEUTICS-UK-LIMITED |
GALMED-THERAPEUTICS-UK-LIMITED |
62%
|
ions to which you are entitled as an investor. 53 If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordi… |
| GALTOPA-THERAPEUTICS-LTD |
GALTOPA-THERAPEUTICS-LTD |
62%
|
. The Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development Ltd. (“GRD”) and Galtopa Therapeutics Ltd., both of… |
| GENERAL-GALMED-PHARMACEUTICALS-LTD |
GENERAL-GALMED-PHARMACEUTICALS-LTD |
62%
|
sure compliance with security, availability and confidentiality trust principles. The cybersecurity process has been integrated into our overall risk management system and process, and is solely inte… |
| HEIGHTS-CAPITAL-MANAGEMENT-INC |
HEIGHTS-CAPITAL-MANAGEMENT-INC |
62%
|
til February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most rece… |
| HOLDERS-CVI-INVESTMENTS-INC |
HOLDERS-CVI-INVESTMENTS-INC |
62%
|
til February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most rece… |
| ISRAEL-GALTOPA-THERAPEUTICS-LTD |
ISRAEL-GALTOPA-THERAPEUTICS-LTD |
62%
|
incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $210.8 million and positive working capital (current assets less current liabi… |
| ISRAEL-LTD |
ISRAEL-LTD |
62%
|
incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $210.8 million and positive working capital (current assets less current liabi… |
| ISRAMEX-PROJECTS-LTD |
ISRAMEX-PROJECTS-LTD |
62%
|
incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $210.8 million and positive working capital (current assets less current liabi… |
| JONESTRADING-INSTITUTIONAL-SERVIECS-LLC |
JONESTRADING-INSTITUTIONAL-SERVIECS-LLC |
62%
|
d Financial Statements Note 6 – Other Payables Schedule of Other Payables 2025 2024 As of December 31, 2025 2024 (in thousands) Employees and related $ 557 $ 603 Accrued Vacation 283 256 Other 2 6 Ot… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
. Since our initial public offering, the trading price of our ordinary shares has been volatile and is likely to continue to be volatile. In addition, the trading volume is and has been volatile and … |
| NOVO-NORDISK-INC-MADRIGAL-PHARMACEUTICALS-INC |
NOVO-NORDISK-INC-MADRIGAL-PHARMACEUTICALS-INC |
62%
|
cial condition could be adversely affected. Before an NDA is approved, and before we begin the commercial manufacture of any product candidate, contract manufacturers must register with the FDA, MHRA… |
| SAMIL-PHARMA-CO-LTD |
SAMIL-PHARMA-CO-LTD |
62%
|
ions to which you are entitled as an investor. 53 If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordi… |
